The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology

Stockholm, Sweden – August 23, 2022. Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.

The integration between Sectra and Stratipath will give the possibility of novel deep learning image analysis integrated into the existing digital pathology workflow. Stratipath’s solution for risk stratification of breast cancers, Stratipath Breast, provides novel decision support for clinicians in the diagnostic evaluation of breast cancer.

Stratipath Breast is the first EU regulatory compliant solution for risk stratification of breast cancer using AI-based precision diagnostics to analyse cancer tissue, and enabling identification of patients with increased risk of disease progression. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E), Stratipath Breast enables detection and classification of intermediate risk tumours into low- and high-risk groups, based on grade-related tumour morphology. Hereby, the results provide novel decision support to clinicians and enables precision medicine for more breast cancer patients.

In contrast to traditional molecular tests for risk stratification, AI-based risk stratification enables faster turnaround times for results, provides new information at the point of diagnosis and reduces the need for expensive molecular testing, allowing for wider use and benefit to more patients.

“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs,” says Johan Hartman, professor in pathology at Karolinska Institutet, Stockholm, and co-founder of Stratipath.

About Sectra
With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider to health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. For more information, visit Sectra’s website.

About Stratipath
Stratipath brings together physicians, researchers, AI-scientists, developers and industry specialists with its aim to help all patients get the right treatment through precision diagnostics. Stratipath is a spin-out from Karolinska Institutet in Stockholm, Sweden, bringing pioneering research from the fields of AI and precision medicine into clinical use. The company was founded in 2019 with a mission to radically improve cancer treatment decisions and patient outcomes. Stratipath uses AI technology and research to improve cancer diagnostics for more patients. Today far too many patients receive inconclusive cancer diagnoses and have unequal access to precision diagnostics. Stratipath’s AI technology can change this by providing patients with faster access to novel, more conclusive and precise results, at a sustainable cost.

The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.

Read More »

Government grant to provide more accurate breast cancer diagnosis

Vinnova grants SEK 20 million to the Swedish AI Precision Pathology (SwAIPP) consortia to develop and implement AI-based precision diagnostics in cancer care. The consortia consist of Stratipath, Karolinska Institutet, the pathology clinics in the Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas and Helseplan.

Read More »

Annals of Oncology

analysis can stratify intermediate-grade breast cancers into low or high grade. This has strong prognostic value and potential to revolutionize breast pathology.

Read More »

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more